Company intelligence / Profile preview

BrainXell

Madison, Wisconsin, United Statesbrainxelltx.com ↗

Ownership: Private
Employees: ~70
Development stage: Preclinical

Overview

BrainXell provides high-purity, iPSC-derived human neurons and glia for research and drug discovery. The company’s proprietary technology enables scalable production of specialized neural cells. While primarily a supplier to pharma/biotech R&D, it also aims to develop stem cell therapies for neurological conditions through industry collaborations. No clinical trial results have been published as of June 2025.

Therapeutic areas: Neurology
Modalities: Induced pluripotent stem cell derived therapyCell therapyStem cell therapy
Industry: Biotech

Partnerships

Collaborates with pharmaceutical and healthcare companies on research projects.

Beyond the preview

Go deeper on BrainXell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BrainXell.

Explore the full profile